

RESEARCH

Open Access



Synthetic nanoparticles for cell-type specific, spatially resolved loading and export of MiRNAs in neural cells

Marianna Mignanelli¹, Giacomo Siano^{1,2}, Vincenzo Iannone², Arianna Scarlatti¹, Emanuele Orsini³, Ludovico Maggi¹, Milena Rizzo⁴, Maria Claudia Caiazza^{5,6}, Richard Wade-Martins^{5,6}, Alessandra Salvetti⁷, Greta Ghiloni¹, Federico Cremisi¹, Valentina Casieri⁸, Lorenzo Fruzzetti², Elena Novelli², Ali Ataman², Antonino Cattaneo^{1*} and Cristina Di Primio^{2*}

Abstract

Background Brain development and plasticity depend on specific microRNA (miRNA) expression patterns across cell types and subcellular compartments. Nevertheless, comprehensive profiling of localized brain miRNAs is still limited by challenges in isolating individual cell types or compartments and in detection sensitivity.

Results To overcome these limitations, we advanced HIV-1 Gag's ability to bind host miRNAs within Virus-like Particles to develop Synthetic Nano-Particles for Precise endogenous miRNA loading and export (SNaP). Our data establish SNaP's modularity and portability to clinically relevant neural cells, with particle yields matching benchmark packaging cells. The integration of SNaP with a cell-specific promoter enabled lineage-restricted miRNA export, while incorporating a dendritic localization signal improved the specificity of post-synaptic miRNA recovery over traditional synaptosomes. Additional engineering with a miRNA-binding module synergistically increased synaptic miRNA packaging in a sequence-independent manner.

Conclusion Collectively, this work positions SNaP as a technological advancement supporting the high-resolution, spatially resolved profiling of miRNAs, adaptable to diverse polarized or heterogeneous culture systems.

Keywords MiRNA, Synthetic Nano-Particles (SNaP), HIV-1 gag Virus-Like particles, Cell type-specific, Dendritic localization signal, Spatial resolution


*Correspondence:
Antonino Cattaneo
antonino.cattaneo@sns.it
Cristina Di Primio
cristina.diprimio@cnr.it

Full list of author information is available at the end of the article



Graphical Abstract

SNaP: Gag-based nanoparticles for spatially resolved neuronal miRNome profiling



Background

MicroRNAs (miRNAs) are small, noncoding RNAs that serve as ubiquitous regulators of gene expression, orchestrating fundamental biological processes through post-transcriptional control [1]. In the central nervous system (CNS), miRNAs are dynamically regulated during development and exhibit cell type-specific expression in the adult brain, underscoring their essential role in neuronal identity and function [2–5]. In addition to their compartmentalized expression, specific miRNA populations localize within synaptic compartments, where they modulate activity-dependent gene expression of plasticity-related products via translational control [6–10]. Given their critical role in brain homeostasis, miRNA dysregulation is linked to a wide range of neurological disorders [11, 12]. Consequently, miRNAs are emerging as attractive candidates for CNS biomarker discovery, with the potential to surpass protein-based predictors in both sensitivity and specificity for early diagnosis [13].

Nevertheless, the implementation of brain miRNAs as CNS biomarkers remains challenging. Current approaches for local transcriptomics, such as those based on synaptosome isolation or microdissected neuropils, suffer from contamination by neighbouring cells or sub-cellular compartments, hindering accurate assignment of miRNA topology [14–16]. Moreover, bulk miRNA

sequencing lacks the sensitivity to detect rare, spatially restricted miRNA species [17, 18]. On the other hand, single-cell small RNA profiling is still far from being widely and easily applicable to regionalized miRNAs because of their short length and adapter ligation biases [19]. Collectively, these limitations constrain our understanding of localized posttranscriptional regulation in the CNS and highlight the need for alternative strategies offering both increased spatial resolution and increased detection sensitivity [20].

Virus-like particles (VLPs) derived from the HIV-1 Gag polyprotein offer a promising platform in response to these challenges [21]. Gag self-assembles into VLPs through interactions with specific RNA motifs, a mechanism that naturally facilitates the selective encapsidation of RNAs—including host miRNAs—during HIV-1 replication [22, 23]. Moreover, Gag exhibits substantial structural flexibility, tolerating genetic fusion with exogenous domains without compromising particle assembly or function [24]. These features have recently enabled the development of modular VLPs with programmable RNA-binding specificity and ancillary features [25].

In this study, we present SNaP (Synthetic Nano-Particles for Precise miRNA loading and export), a Gag-based VLP platform designed to enable targeted recovery of endogenous miRNAs from complex CNS cell types. The

SNaP system integrates modular domains to achieve (i) cell type-specific miRNA loading, (ii) subcellular compartment targeting, and (iii) enhanced miRNA detection. We further demonstrated the feasibility of applying SNaP in both neuronal and microglial cell types by equipping SNaP constructs with cell-specific transcriptional control, highlighting its robustness in challenging cellular and tissue environments.

Overall, this work positions SNaP as a novel and versatile tool for spatially resolved, cell type-specific miRNA profiling in the CNS. Its modular design and compatibility with heterogeneous cell types establish a foundation for high-throughput applications in biomarker discovery and the investigation of compartmentalized RNA regulation in any clinically relevant tissue.

Methods

Cell culture

Human embryonic kidney (HEK-293T) cells (ATCC CRL-3216), immortalized HT22 hippocampal neurons, and immortalized BV-2 microglia were cultured routinely in Dulbecco's modified Eagle's medium (DMEM) with low glucose (EuroClone). The medium was supplemented with 10% heat-inactivated fetal bovine serum (FBS; EuroClone), 100 U/mL penicillin, and 100 µg/mL streptomycin (Sigma Aldrich, Milan, Italy). All the cell lines were maintained under standard conditions at 37 °C with 5% CO₂.

Human integrated, inducible, and isogenic (i³) iPSCs (as described by Wang et al. [58]) were generously provided by Dr. Michael Ward from NINDS/NIH. Cell handling and differentiation followed the protocol outlined by Fernandopulle et al. [59] (the detailed procedure is outlined in the *Supplementary Information*). Culturing was performed until mature polarity was observed (4 weeks in vitro, as previously described by Wang et al., 2017 [58]).

The handling and differentiation of mouse embryonic stem cells (mESCs) from the E14Tg2A line were performed according to the methods described by Bertacchi et al. [60], and Lupo et al. [61] (refer to the *Supplementary Information* for a complete description). The cells were cultured until they reached full maturation, as described in Bertacchi et al. [60].

Molecular cloning

Chimeric Gag proteins were cloned from an initial donor vector expressing the Rev-independent, codon-optimized HIV-1 Gag coding sequence, fused in frame with eGFP, and under the control of the CMV promoter (pGag-eGFP, courtesy of the NIH AIDS Reagent Program, cat ARP11468).

SNaP-CSP constructs were generated as follows: the Gag insert from the pGag-eGFP plasmid, digested with

BssHII and BamHI, partially overlapped with the pAAV-CamKII vector (Addgene, cat. 64545), linearized with EcorV and BamHI, or the pAAV-mIba1 backbone (Addgene cat. 190163), and digested with AgeI and NotI.

To generate Gag-TRBP constructs, the two double-strand RNA-binding domains (dsRBD1 and dsRBD2) from TRBP were amplified via PCR from the pcDNA-TRBP template (Addgene, cat. 15666) via the following primers to facilitate the insertion of an N-terminal, hydrophilic, 33 bp flexible linker (sequence: NRNGDP-PVATM, GRAVY hydrophobicity score: -1.04) along with the BamHI and NotI restriction sites to facilitate cloning: forward primer: 5'AAAACAGAAACGGGGATCCACCGGTCGCCACCATGGCGAT-3'; reverse primer: 5'-TCTAGAGCGGCCGCTTACAGCATTT-3'. The resulting linker-TRBP insert was subcloned downstream of the Gag sequence of the pGag-eGFP construct via BamHI and NotI restriction digestion.

To express chimeric Gag proteins in i³ neurons and mouse embryonic stem cell (mESC)-derived neurons, the BssHII- and NotI-digested Gag insert from pGag-eGFP was subcloned and inserted into the pBOB-EF-1-Fast-FUCCI-Puro vector (Addgene, cat. 86849) upon removal of the FUCCI cassette via the same enzyme set (final construct: pBOB-EF-1α-Gag). To generate the pBOB-EF-1α-Gag-DLS construct, a 247 bp sequence corresponding to the dendritic localization signal (DLS) was amplified from the *Psd95* transcript, as described by Subramanian et al., 2011. This sequence was contained in a pCDNA3.1 vector (courtesy of the Laboratorio di Biologia Bio@SNS at Scuola Normale Superiore). PCR primers with BamHI and NotI restriction sites were used for amplification (forward primer: 5'-ATAGGATCCTTAATGGCTTTTTTTT TTTTCT-3'; reverse primer: 5'-ATAGCGGCCGCGTC TGTCTCTT-3'). These sites facilitated restriction-mediated cloning of the DLS sequence downstream of the stop codon in pBOB-EF-1α-Gag. For the pBOB-EF-1α-Gag-TRBP-DLS construct, we added the TRBP sequence to the pBOB-EF-1α-Gag-DLS vector linearized with NotI.

SNaP production

HT22/BV-2 cocultures. Both cell lines were pretreated with the neutral sphingomyelinase inhibitor GW4869 (Sigma Aldrich, cat. 6823-69-4) at a concentration of 10 µM for 2 h to partially inhibit extracellular vesicle (EV) secretion. GW4869-conditioned cells were then cocultured at an HTT/BV-2 ratio of 110.000/60.000 and maintained under standard culture conditions as described above. The next day, the cocultures were transfected with Lipofectamine 2000 (Thermo Fisher Scientific) or Glial-Mag (OZ Biosciences) to induce transient expression of pAAV-CamKII-Gag or pAAV-mIba1-Gag, respectively. A total of 4 µg of pAAV-CamKII-Gag and 3 µg of pAAV-mIba1-Gag per well were used, following the

manufacturers' protocols. Mock-transfected cells were used as controls. The culture medium was collected at 48 and 72 h post-transfection, centrifuged at 1,200 rpm for 5 min, and filtered through a 0.45 μm PES filter to remove cellular debris. SNaP particles were concentrated approximately 500-fold by ultracentrifugation on a 20% (w/v) sucrose cushion in PBS.

i^3 neurons and mESC-derived neurons Doxycycline-induced i^3 neural progenitors were seeded onto Geltrex-coated 10 cm culture dishes at a density of 10 million cells per plate. During plating, the cells were transduced with VSV-G-pseudotyped lentiviral vectors expressing pBOB-EF1 α -Gag, pBOB-EF1 α -Gag-DLS, or empty pBOB-Ef1 α constructs (details on neural progenitor transduction are provided in the *Supplementary Information*). The medium was fully replaced the following day, and the neurons were maintained for four weeks in culture. mESC-derived neural progenitors were seeded at a density of 125,000 cells/cm² on polyornithine- and laminin-coated wells at DIV7. They were then transduced with pBOB-EF1 α -Gag-DLS, pBOB-EF1 α -Gag-TRBP-DLS, or control pBOB-EF1 α lentiviral vectors as described in the *Supplementary Information*. Mock-transduced cells were used as controls. Following lentiviral incubation, the culture medium was replaced with neurobasal A, and the neurons were cultured until full maturation (typically by DIV28), with daily medium replacement. SNaP particles from both i^3 and mESC-derived neurons were harvested from the media of DIV25 and DIV28 mature cells and purified as described above.

HEK-293T cells: Cells were seeded onto 10 cm culture dishes at a density of 5 million cells and cotransfected the next day with PEI. Transfections were performed using 25 μg of either pGag-eGFP or pGag-TRBP (control: Gag-free vector) and 5 μg of the VSV-G plasmid, maintaining a 5:1 ratio. PEI/DNA complexes were formed in serum-free low-glucose DMEM and incubated for 10 min at room temperature before being added to the cells. Mock-transfected cells were used as controls. The cells were then maintained overnight in Opti-MEM (Gibco) medium. The following day, the culture medium was supplemented with the EV inhibitor GW4869 (final concentration of 10 μM). SNaP were then purified from culture media collected at 48 and 72 h post-transfection as described above.

Nanoparticle tracking analysis (NTA)

Quantification of VLPs was performed using a NanoSight[®] LM10 device (NanoSight Ltd., Amesbury, UK) equipped with a 405 nm laser and NTA 2.3 analytic software. Samples were diluted in 0.22 mm-filtered PBS prior to injection in the device chamber, in order to obtain samples with a concentration around 1×10^7 – 1×10^9 particles/ml. Three injections of the sample and three

independent analyses were carried out using a syringe manual pump. Particles were identified and tracked by their Brownian motion at room temperature. Setting parameters were: camera level: 12, screen gain: 10, detection threshold: 2. NTA2.3 analytic software allowed determining the number of VLPs/mL from the tracking data. Only nanoparticles in the range of 100- to-200 nm were quantified.

Titration of snap particles

The physical titre of SNaP particles was determined via a commercial enzyme-linked immunosorbent assay (ELISA) specific for the detection of the HIV p24 core antigen in cell culture supernatants (Innotest HIV antigen mAb assay; Fujirebio, cat. 81512) according to the manufacturer's instructions. The absorbance was measured at 450 nm for p24 quantification, and the antigen concentration was determined by generating a standard curve from the control and performing linear regression analysis.

SNaP cargo RNA extraction

A 300 μL aliquot of concentrated SNaP particle suspension was treated with RNase A (2 $\mu\text{g}/\mu\text{L}$) for 15 min at 37 °C to degrade any extravesicular RNA. Total RNA was then isolated from both SNaP particles and producer cells via the miRNeasy Micro Kit (Qiagen, cat. 217084). While the standard protocol was applied for cell pellet samples, modifications were implemented for viral particle preparations. Specifically, after a 5-minute incubation in Qiazol lysis reagent (Qiagen), 10 mg/mL glycogen was added to the solubilized SNaP samples to increase miRNA recovery. Phase separation was performed by adding 200 μL of chloroform, followed by RNA purification according to the manufacturer's instructions. RNA purity was assessed via UV spectrophotometry. For cellular RNA, ribosomal RNA integrity was evaluated by confirming the 28 S:18 S rRNA ratio of 2:1, whereas RNA integrity from SNaP particles was assessed via automated electrophoresis, as described in the *Supplementary Information*.

Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and determination of snap MiRNA packaging efficiency

For cDNA synthesis, 1 μg of cellular RNA or 100 ng of SNaP RNA was reverse transcribed via the miR-X miRNA First-Strand Synthesis Kit (Takara, cat. 638315) according to the manufacturer's protocol. RT-qPCR was performed on 5 μL of cDNA (diluted 1:100) in a total reaction volume of 20 μL using SSO Advanced Universal SYBR Green Supermix (Bio-Rad, cat. 1725271). The forward primers were specific to the mature miRNA sequences, whereas the universal reverse primer provided with the kit targeted the poly(T) adapter sequence

incorporated during cDNA synthesis. A comprehensive list of primers used is available in the *Supplementary Information, Table 2*. PCR amplification was conducted on a Rotor-Gene Q cycler (Qiagen) with the following thermal cycling conditions: initial denaturation at 95 °C for 2 min, followed by 35 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 30 s. Primer specificity was verified by performing melting curve analysis from 65 °C to 95 °C, with increases in 0.5 °C increments per second.

Relative quantification of miRNA expression in packaging cells was performed via the standard $\Delta\Delta C_t$ method [62], with U6 small nuclear RNA serving as the reference gene for normalization. For SNaP particle samples, as a suitable reference gene was unavailable, miRNA expression was determined via the ΔC_t method, ensuring that equal amounts of input total RNA were used for all samples, in line with recommendations by Livak and Schmittgen [63]. ΔC_t s was determined as the difference between the C_T values of SNaP particles and those obtained from the supernatant of matching mock-transfected/transduced cultures. To quantify the extent of miRNA encapsidation attributable to SNaP engineering, the expression levels obtained from chimeric particles were normalized to those from the corresponding benchmark samples. This ratio produced fold enrichment values, which we defined as “miRNA recovery efficiency”. The components of each comparative analysis are specified in the respective figures.

Immunofluorescence and quantification analysis

HT22 and BV-2 cocultures were established by seeding 8,000 HT22 cells and 5,000 BV-2 cells per well in 8-well chamber slides (Nunc Lab-Tek, Thermo Fisher Scientific). The following day, transfection was performed with 250 ng of pCamkII α -Gag plasmid for HT22 cells or 100 ng of pIba1-Gag plasmid for BV-2 cells via *Lipofectamine 2000* (Thermo Fisher Scientific) for neuronal cells and GlialMag Transfection Reagent (OZ Biosciences) for microglia, in accordance with the manufacturer’s protocols. After 24 h, the medium was replaced, and the cultures were maintained for an additional 48 h. Doxycycline-induced i^3 progenitors and DIV7 mESC-derived neuronal progenitors were seeded onto glass coverslips coated with Geltrex or polyornithine, respectively, at a density of 100,000 cells/cm². Lentiviral transduction with pBOB-Gag or pBOB-Gag-DLS vectors was carried out as described in the *Supplementary Information*. Following transduction, the medium was changed after 24 h, and the cells were cultured under standard differentiation conditions until full maturation.

HT22/BV-2 cocultures and i^3 neurons were fixed in 4% paraformaldehyde (PFA), rinsed in PBS, and permeabilized with 0.1% Triton X-100 for 5 min at room temperature. After additional PBS washes, nonspecific binding

was blocked by incubation in 1% (w/v) BSA for 30 min. mESC-derived neurons were fixed in 2% PFA, blocked for 1 h in PBS supplemented with 3% (w/v) BSA and 3% (v/v) FBS, and permeabilized in 0.5% (w/v) Triton X-100 in PBS. All the samples were then incubated overnight at 4 °C in a humidified chamber with primary antibodies diluted in blocking buffer (the antibodies used are listed in *Supplementary Table 1*). The following day, after washing in PBS, Alexa Fluor-conjugated secondary antibodies (*Supplementary Information, Table 1*) were applied for 2 h at room temperature. Nuclear counterstaining was performed with DAPI (1:10,000) for 10 min.

Optical Sect. (2186 × 2186 or 3458 × 3458 pixels) were acquired via a Leica STELLARIS 5 confocal microscope. Smaller image sets consisted of cropped regions derived from the larger fields of view to ensure comparability across datasets. Each pixel corresponded to an area of 0.035 × 0.035 μm^2 . Super-resolution images were additionally acquired for i^3 neurons using a Zeiss LSM 900 confocal microscope equipped with an Airyscan 2 detector (Carl Zeiss, Jena, Germany), using 63x/1.4 Plan-Apochromat oil-immersion objective. Images were sampled at a resolution of 2186 × 2186 pixels. Serial optical sections were collected as z-stacks at 0.2 μm intervals.

To ascertain p24 cell-specific expression in HT22/BV-2 co-cultures expressing cell type-restricted SNaP particles, we quantified the p24 signal intensity in microglial- and neuronal-like cell types within Neuro-SNaP and Microglia-SNaP particle production, respectively. As the specificity of the fluorescent signal for the neuronal antigen HuC/D was insufficient to reliably discriminate the two cell types across the entire population, an additional selection step was introduced to identify cells that could be unambiguously classified as either neurons or microglia. Following such a selection, p24 fluorescence intensity was determined for each cell type in both Neuro-SNaP and Microglia-SNaP conditions. Specifically, cells were first selected based on a clear, spatially isolated DAPI signal. For each identified cell, the centre of the analysis region was then defined by the experimenter as the center of the DAPI signal. Multiple concentric circles were subsequently generated from the center of the nucleus, and p24 fluorescence density was then computed as a function of radial distance. We then defined the average nuclear radius as the distance at which the fluorescence density reached its maximum. Following p24 quantification, fluorescence intensity was also determined for the two cell-type-specific markers, with CD11b as a microglial and HuC/D as a neuronal marker, by following the same radial profiling algorithm as described above. All the features are then zscored to allow for better comparison between them. This procedure yielded three features for each cell: maximum p24 signal, maximum CD11b signal, and maximum HuC/D signal. To clearly classify cells

belonging exclusively to one of the two cell type classes (HT22 or BV-2), we subsequently examined the distribution of fluorescence intensity for HuC/D and CD11b per each selected cell. Two intensity thresholds were defined, one for HuC/D and one for CD11b, both set to the average fluorescent intensity of the entire population. Cells were classified as neurons if the HuC/D signal was high while the CD11b signal was low, and as microglia if the CD11b signal was high while the HuC/D signal was low. Cells not meeting one of these criteria were excluded from further analysis. From the resulting neuron- and microglial- classified populations, p24 intensity was eventually compared between the two co-cultured cell types within each experimental condition.

For experiments involving i^3 neurons, quantitative analyses were performed using a custom Python script. With this regard, soma and neuronal extensions of p24 positive neurons were manually selected. Dendritic extensions were then identified and traced based on the Homer 1b/c signal. To estimate the average somatic fluorescence density, a radial profiling approach was applied by generating multiple concentric circles from the center of the soma and computing fluorescence density as a function of radial distance. The radius at which fluorescence density peaked was taken as an estimate of the average somatic radius. Somatic fluorescence density was then calculated as the mean fluorescence intensity within a distance ranging from 0 to twice this average radius. To quantify dendritic p24 fluorescence density, a dendritic mask was generated by tracing a line following the manually selected dendritic extensions with a fixed width of 10 pixels. Pixels in close proximity to the soma were excluded from the dendritic mask by removing all points within a distance equal to four times the average somatic radius determined in the previous step. The average dendritic fluorescence density was calculated as the mean fluorescence intensity within the resulting dendritic mask. For each neuron, a soma-to-dendrite fluorescence ratio was then computed by dividing the average somatic fluorescence density by the average dendritic fluorescence density. Higher ratios correspond to relatively greater somatic fluorescence compared with dendritic fluorescence.

Statistical analysis

Statistical analysis and graphical representations were performed via Prism 8.0.2 (GraphPad Software Inc., CA, USA). To compare multiple groups, nonparametric Kruskal–Wallis tests followed by Dunn’s multiple comparisons post hoc test were used. For comparisons between two groups, Student’s *t* test, the Mann–Whitney *U* test, or Mood’s median test was applied, depending on the experimental design, as specified in the Fig. legends. A two-sided *p* value less than 0.05 was deemed statistically

significant, with significance levels represented as * for $p < 0.05$, ** for $p < 0.01$, *** for $p < 0.001$, **** for $p < 0.0001$, and “n.s.” for nonsignificant results. Exact *p* values and further details regarding data presentation are provided in the respective figure legends.

Results

Cell-specific snap packaging enables confined endogenous MiRNA loading and export

Brain miRNAs display distinct cell type-specific expression patterns crucial for CNS development and function; nevertheless, accurately profiling their signatures in individual brain cells remains challenging [26]. To improve the resolution of endogenous miRNA profiling at the cell type level, we exploited and advanced the inherent capacity of HIV-1 Gag virus-like particles (VLPs) to package host RNAs [23] by incorporating additional functional modules, resulting in the development of synthetic nanoparticles for precise miRNA loading and export (SNaP). The first innovation at the core of this platform is the integration of a cell-specific promoter to drive Gag expression [27], thereby limiting SNaP nanoparticle formation and contextual miRNA export to desired cell populations.

To validate this strategy, we established a simplified model of CNS cellular diversity using cocultured immortalized hippocampal neurons (HT22) and microglia (BV-2). We first performed a marker screen in individually cultured cells to establish identification criteria: we identified BV-2 cells as CD11b-positive, whereas HT22 cells as CD11b-negative, HuC/D-positive, consistent with expected labelling patterns [28, 29] (*Supplementary Fig. 1A*). In cocultures, we then transiently directed SNaP production via either the *CaMKII α* or the *Iba1* modules, enabling the selective generation of Neuronal- or Microglia-SNaP nanoparticles, respectively [30, 31] (*Fig. 1A*). Immunostaining for the Gag p24 domain suggested that Gag expression was limited to the intended cell types (*Fig. 1B* and *Supplementary Fig. 1A, B*), a finding corroborated by the quantification of p24 fluorescence intensity in microglial- and neuronal-like cells; specifically, the Gag domain was preferentially detected in CD11b-positive microglia following Microglia-SNaP production in co-cultures, and, vice versa, in HuC/D-positive neurons following Neuro-SNaP expression (*Fig. 1C*). Importantly, although SNaP expression in HT22 and BV-2 was of moderate efficiency, the resulting p24 antigen concentrations indicated strong nanoparticle yields from both neuronal and microglial sources, supporting their suitability for downstream RNA applications (*Fig. 1D* and *Supplementary Fig. 1C*). In addition, Nanoparticle Tracking Analysis confirmed that SNaP particles generated in non-standard neuronal- or microglial-like cell types exhibited the expected size previously reported for




Fig. 1 SNaP nanoparticles efficiently package neuronal or microglial miRNAs in a brain cell coculture system. **A**) Schematic representation of the experimental setup for the targeted production of the SNaP tool via a cell-specific promoter domain in HT22/BV-2 cocultures. **B**) Representative confocal images showing cell-specific Gag expression (p24, yellow) in HT22 (neuronal marker HuC/D, red) and BV-2 cells (microglial marker CD11b, green). Mock-transfected cocultures were used as controls. Nuclei were counterstained with DAPI (blue). Scale bar: 10 μm . **C**) Quantification of p24 maximum signal intensity in microglial- and neuronal-like cell types within Neuro-SNaP and Microglia-SNaP particle production (further details on the analysis pipeline available in *Methods*). Data shown as zscore for better comparison between them and presented as boxplots representing median p24 intensity with range (whiskers). Mann–Whitney U test: Neuro-SNaP ($p=0.0048$, $U=71$), Microglia-SNaP ($p<0.0001$, $U=76$). **D**) Quantification of p24 levels in supernatants from cocultures transfected with Neuro-SNaP or Microglia-SNaP constructs. The data are presented as the means \pm SEMs ($n=4$ independent replicates). Mann–Whitney U test: $p=0.100$, $U=3$ (not significant). **E**) Comparative assessment of miRNA recovery efficiency in Microglia-SNaP relative to Neuro-SNaP (for *mmu-miR-127* and *mmu-miR-433*) and in Neuro-SNaP versus Microglia-SNaP (for *mmu-miR-142* and *mmu-miR-223*). The definition of miRNA recovery efficiency is provided in the Materials and Methods. Data adjusted for background miRNA levels detected in the medium from mock-transfected cocultures and normalized against the unit mass of the assessed miRNAs. Boxplots represent median fold changes with ranges (whiskers). Mann–Whitney U test: *mmu-miR-127* ($p=0.0079$, $U=0$), *mmu-miR-433* ($p=0.023$, $U=6$), *mmu-miR-142* ($p=0.028$, $U=0$), *mmu-miR-223* ($p=0.04$, $U=5$)

chimeric Gag-like particles packaged in canonical models [24], with an average diameter mode of 133 nm and 130 nm, respectively (*Supplementary Fig. 1D*).

To further assess the specificity of the SNaP system for cell-specific miRNA characterization, we performed RT-qPCR on RNA extracted from supernatants and compared the composition of miRNAs embedded within neuronal and microglial particles. SNaP particles generated by *CaMKII α* -driven expression preferentially encapsulated *mmu-miR-127* and *mmu-miR-433*, which we previously identified as neuron-enriched (Fig. 1E and *Supplementary Fig. 1D*). Conversely, the *Iba1*-driven SNaP efficiently packaged the microglia-associated miRNAs *mmu-miR-142* and *mmu-miR-223* (Fig. 1E and *Supplementary Fig. 1E*). Notably, overall miRNA expression levels were comparable between cultures expressing SNaP and mock controls, indicating that the observed selective loading was due to restricted nanoparticle production rather than changes in endogenous miRNA levels (*Supplementary Fig. 1F*).

Collectively, these results establish SNaP as a versatile and effective platform for specifically capturing miRNAs into cell type-specific SNaP and thereby isolating miRNAs from defined cell types within the complex cellular milieu of the brain. By enabling the selective export of miRNAs directly from targeted cell populations in situ, SNaP addresses critical obstacles of cell resolution and tissue accessibility that constrain conventional brain cell-specific transcriptomic approaches.

The DLS module confers high specificity for snap dendritic, post-synaptic miRNA isolation

Current miRNA profiling transcriptomic techniques are limited not only in terms of cell-type resolution but also in accurately profiling miRNAs within specialized sub-cellular compartments, such as neuronal dendrites and axons, where local miRNAs play essential roles in modulating synaptic plasticity [14, 32].

To address this challenge, building on the demonstrated effectiveness of SNaP for in situ miRNA loading and export in specific cell types, we designed an additional module to restrict miRNA profiling at the sub-cellular level, specifically targeting the dendritic region of neurons. To increase virus-like particle-mediated miRNA loading within dendrites, we incorporated a 247-nucleotide dendritic localization signal (DLS) from the 3' UTR of the *PSD95* transcript into the 3' UTR of the Gag mRNA. This sequence is well established to be both necessary and sufficient for directing mRNA transport specifically to dendrites [33], thereby increasing the likelihood of VLP assembly in the dendritic/post-synaptic compartment, allowing, in principle, enrichment of the loading of dendritic miRNAs while minimizing


the contamination of miRNAs from pre-synaptic and somatic regions.

To validate the effectiveness of the dendritic-targeting module, we transduced human iPSC-derived neuronal progenitors with VSV-G-pseudotyped lentiviral vectors encoding either the SNaP-DLS construct or a benchmark SNaP-only variant with no specific RNA localization sequence. Following viral transduction, cells were differentiated into cortical glutamatergic neurons, and the supernatants were harvested at 25 and 28 days post-differentiation (DIV25 and DIV28) to concentrate the released virus-like nanoparticles (Fig. 2A and *Supplementary Fig. 2A*). Super-resolution microscopy confirmed that neuronal maturation in SNaP-packaged cultures proceeded comparably to mock-transduced control cells, suggesting minimal disruption of neuronal physiology upon nanoparticle formation and budding (Fig. 2B).

DLS engineering produced clear differences in nanoparticle localization. While neurons expressing the untargeted SNaP construct exhibited diffuse p24 immunoreactivity across both soma and dendrites, cells expressing SNaP-DLS showed significantly greater p24 signal intensity within dendrites relative to cell bodies (Fig. 2B). Quantitative analysis confirmed that the incorporation of the DLS module within SNaP skewed p24 fluorescence towards the dendritic compartment, consistent with selective dendritic targeting (Fig. 2C). Notably, SNaP particles remained readily detectable in the supernatant for up to four weeks of differentiation (Fig. 2D). Moreover, this engineered targeting did not compromise overall miRNA export capacity, as sufficient total RNA levels were recovered for downstream analysis regardless of the spatial restriction of SNaP-DLS (*Supplementary Fig. 2B*).

To assess whether the enhanced SNaP-DLS post-synaptic localization confers functional specificity for dendritic miRNA isolation, we examined the modules' capacity to load three miRNA species with established dendritic and post-synaptic localization: *hsa-miR-132*, *hsa-miR-134*, and *hsa-miR-138* [35]. Indeed, according to the engineered design, SNaP-DLS nanoparticles demonstrated greater enrichment of these molecules than untargeted SNaP-only controls did (Fig. 2E). In contrast, SNaP-DLS failed to efficiently load three axonal miRNAs and a non-compartmentalized miRNA, underscoring their specificity for dendritic miRNA species (*Supplementary Fig. 2C*). Importantly, lentiviral transduction did not alter overall miRNA expression levels (*Supplementary Fig. 2D*), further validating the integrity of our observations.

Given the precise targeting demonstrated by SNaP-DLS, we next benchmarked its performance against that of state-of-the-art methods. By comparing our qPCR-based profiles to the most comprehensive published dataset of human synaptosomal miRNAs [36], we found



that SNaP-DLS and traditional synaptosomal preparations achieved similar enrichment of *hsa-miR-132* and *hsa-miR-134* (Fig. 2E, left). However, SNaP-DLS exhibited significantly lower recovery of *hsa-miR-361*, a known pre-synaptic miRNA (mean recovery efficiency: 98.38% vs. 1.61%, Fig. 2E, right). This difference highlights the

superior spatial specificity afforded by SNaP-DLS, as opposed to conventional synaptosomal-based methods.

Collectively, these results establish SNaP-DLS as a highly specific and effective platform for isolating dendritic miRNAs, significantly reducing the recovery of the non-dendritic background compared with that of conventional synaptosomes. The DLS module thus provides

(See figure on previous page.)

Fig. 2 Engineering SNaP-DLS for enhanced post-synaptic targeting in human cortical glutamatergic neurons. **A**) Schematic overview of the experimental design for SNaP-DLS production in human neurons. **B**) Representative super-resolution images of DIV28 neurons expressing SNaP or SNaP-DLS. Gag localization is visualized via p24 staining (green), post-synaptic compartments by Homer 1b/c (red), and nuclei by DAPI (blue). Mock-transduced neurons serving as controls. Scale bar: 10 μm . **C**) Somatic-to-dendritic ratio of p24 fluorescence density, with dendritic extensions defined by Homer 1b/c signal (as described in *Methods*). Data presented as boxplots (median with range) from $n = 12$ neurons (SNaP) and $n = 15$ neurons (SNaP-DLS) obtained across $n = 2$ independent experiments. Unpaired, two-tailed t test with Welch's correction: $p = 0.0043$, $t = 3.144$. **D**) p24 antigen levels in the DIV25-DIV28 supernatants of i^3 neurons expressing SNaP or SNaP-DLS constructs. The data are presented as the means \pm SEMs ($n = 3$ independent particles per group). Mann-Whitney U test: $p = 0.100$, $U = 0$ (not significant). **E**) miRNA recovery efficiency in SNaP-DLS relative to SNaP for *hsa-miR-132*, *hsa-miR-134*, and *hsa-miR-138*. The definition of miRNA recovery efficiency is provided in the *Materials and Methods*. Boxplots show the median fold change with range adjusted for background miRNA levels in mock-transduced controls ($n = 3-4$ productions per group). Mann-Whitney U test: *hsa-miR-132* ($p = 0.043$, $U = 0$), *hsa-miR-134* ($p = 0.043$, $U = 0$), and *hsa-miR-138* ($p = 0.043$, $U = 0$). **F**) Comparison of miRNA recovery efficiency between synaptosomes (Kumar et al., 2022) and SNaP-DLS for *hsa-miR-132*, *hsa-miR-134* (post-synaptic), and *hsa-miR-361* (pre-synaptic). The data represent the fraction of the total detected miRNA abundance in the combined synaptosome and SNaP nanoparticle datasets ($n = 4-5$ per group). Adjusted p values from Student's t test with Holm-Sidak correction: *hsa-miR-361* ($p < 0.000001$, $t = 16.24$), *hsa-miR-132* ($p = 0.95$, $t = 0.06$, ns), *hsa-miR-134* ($p = 0.063$, $t = 2.66$, ns), and *hsa-miR-138* ($p < 0.000001$, $t = 14.93$)

an advanced tool for resolving the intricate landscape of compartmentalized miRNA expression, offering unprecedented precision for investigating neuronal miRNomes.

SNaP engineering with a TRBP module significantly boosts unbiased miRNA loading and export

Another major challenge in endogenous miRNA profiling, especially at the subcellular level, derives from their inherently short length and low abundance. This often limits the detection sensitivity for rare or transiently expressed, localized miRNA populations [37]. To overcome this limitation and enhance endogenous miRNA detection while minimizing co-isolation of other host RNA species, we fused the first two double-stranded RNA-binding domains of the Dicer cofactor TRBP (TAR RNA-binding protein) to the C-terminus of Gag. These modules were chosen for their well-established selective, sequence-independent binding to miRNAs and minimal affinity for other RNA classes [38, 39], and they could be well suited for selective miRNA enrichment in the SNaP system. Additionally, their limited size (approximately 20.59 kDa for the two combined domains) was anticipated to minimally contribute to steric hindrance during VLP assembly.

To initially validate the SNaP-TRBP system, we transiently packaged VLP nanoparticles in HEK-293T cells, a widely used model for recombinant viral particle generation. As a benchmark, we used cells expressing a Gag-eGFP fusion protein, whose structure and assembly are well-documented [40] (Fig. 3A and *Supplementary Fig. 1D*). Immunoblotting for the Gag p24 domain confirmed that both the Gag-eGFP and SNaP-TRBP chimeric proteins were expressed at the expected sizes (~ 80 kDa and ~ 75 kDa, respectively), with no evidence of degradation by host proteases (*Supplementary Fig. 3A, left*). Both variants yielded high particle titres in the supernatant (Fig. 3B and *Supplementary Fig. 3A, right*).

While a slight, not significant, reduction in the p24 concentration was observed for TRBP-engineered particles compared with eGFP-expressing particles (Fig. 3B), this event was not attributable to protein-mediated

toxicity (*Supplementary Fig. 3B*). Furthermore, transmission electron microscopy (TEM) and nanoparticle tracking analysis excluded defects in the particle assembly associated with TRBP fusion. Indeed, SNaP-TRBP particles retained a round morphology, a lipid membrane, and an electron-dense Gag core, which was consistent with the shape and size of reference Gag-eGFP particles (average size mode: 130 nm for Gag-eGFP, and 122 nm for SNaP-TRBP; Fig. 3C and *Supplementary Fig. 1D*). The average p24 protein concentrations for both constructs also aligned with established benchmarks for Gag VLP production in HEK-293T cells [41].

Most importantly, incorporation of the TRBP module led to a marked increase in RNA loading efficiency via the SNaP platform (Fig. 3D). This enhancement was further supported by RNA electrophoresis, which revealed an enrichment of small RNAs (10–40 nucleotides) in SNaP-TRBP particles compared with Gag-eGFP VLPs, which was consistent with selective miRNA packaging (Fig. 3E and *Supplementary Fig. 3C*).

To further substantiate this enhanced specificity, we quantified the levels of the three most abundant miRNAs in HEK-293T cells (*hsa-miR-10a*, *hsa-miR-30e*, and *hsa-miR-186*[42]) that carry RNA isolated from SNaP-TRBP versus Gag-eGFP nanoparticles. Notably, SNaP-TRBP demonstrated significantly greater recovery of all three miRNAs (Fig. 3F). Similarly, the endogenous levels of these miRNAs remained unchanged across conditions, indicating that SNaP production did not disrupt basal miRNA expression (*Supplementary Fig. 3D*).

Collectively, these findings demonstrate that TRBP functionalization substantially enhances the sensitivity and specificity of miRNA detection within the SNaP platform, positioning it as a robust, unbiased tool for miRNA profiling.

SNaP synergistic engineering with TRBP and DLS modules significantly improves spatially-resolved miRNA recovery

Our findings demonstrate that the DLS domain effectively drives SNaP packaging within the post-synaptic dendritic compartment. However, this module does not

intrinsically increase miRNA packaging, as this property remains governed by the Gag core [23, 43]. Given that TRBP engineering markedly improves miRNA detection in gold-standard cell lines, we investigated whether combining the TRBP and DLS modules could synergistically increase SNaP post-synaptic miRNA recovery.

To address the effect of dual functionalization on SNaP performance, we compared SNaP particles incorporating both TRBP and DLS domains (SNaP-TRBP-DLS) with those containing only the DLS domain (SNaP-DLS), both of which are generated in mature mouse neurons (Fig. 4A and *Supplementary Fig. 4A*). The production level of neuronal, TRBP-equipped chimeric SNaP particles was comparable to that observed in HEK-293T cells, as indicated by p24 levels (neurons mean = 100.6 ± 46.95 SEM pg/ μ l, HEK-293T mean = 309 ± 144 SEM pg/ μ l, *Supplementary Fig. 4B* and Fig. 3B, *respectively*), reinforcing the concept that mammalian neurons are capable of generating VLPs at levels comparable to those observed in established gold-standard cell lines. Importantly, TRBP functionalization resulted in an approximately tenfold increase in total RNA packaging efficiency compared with that of non-TRBP controls (SNaP-DLS mean = 26.96 ± 1.24 SEM; SNaP-TRBP-DLS mean = 276.1 ± 128.9 SEM; *Supplementary Fig. 4C*). This enhanced RNA packaging did not compromise dendritic targeting, as indicated by similar levels of colocalization between the SNaP particle signal and the post-synaptic marker Homer 1 b/c for both constructs (mean %ROI colocalized = 11.11 ± 0.97 SEM for SNaP-DLS; 12.22 ± 1.10 SEM for SNaP-TRBP-DLS; Fig. 4B and C). Both constructs notably showed greater colocalization than conventional Gag VLPs did, confirming that targeting specificity was maintained upon dual functionalization (Fig. 4C). Further analysis of total cargo RNA confirmed that the presence of TRBP significantly increased the ability of SNaP-DLS to collect post-synaptic miRNAs (Fig. 4D), independent of any changes in basal miRNA expression within transduced neurons (*Supplementary Fig. 4D*).

Collectively, these results confirm the synergistic benefits of multidomain engineering in the SNaP platform. The combination of precise subcellular targeting (via DLS) with enhanced miRNA packaging (via TRBP) simultaneously and significantly improves both the spatial resolution and the sensitivity of miRNA profiling, enabling robust recovery of compartmentalized miRNAs.

Discussion

This study presents SNaP, an original system to advance the unbiased, spatially-resolved profiling of endogenous, localized brain miRNAs. Notably, in this context “unbiased” refers to the sequence-independent capture of native miRNA populations without exogenous reporter tagging, which overturns the prevailing focus in

retroviral VLP engineering, based on the incorporation of restricted, sequence-tagged therapeutic RNA cargos [25, 52].

Advancing current methods to investigate local transcripts, SNaP is equipped with three functional modules that can operate either independently or synergistically to (i) accurately ascertain cell type-specific miRNA expression with minimal environmental interference, (ii) attain unparalleled spatial resolution for discriminating localized miRNA pools, and (iii) increase the sensitivity of miRNA detection. In this proof-of-concept study, these properties were validated using a focused panel of well-characterized miRNAs as model cargos.

Our approach is based on the unique ability of retroviral Gag polyproteins to interact with host noncoding RNAs during viral particle assembly [22, 23]. Leveraging this property, we selectively expressed Gag in specific brain cell types to enable the encapsulation of cellular miRNAs within engineered virus-like particles (VLPs) [44]. Among retroviruses, the HIV-1 Gag polyprotein was chosen as the foundation of our system because of its well-described ability to bind a broad range of host RNA species, potentially facilitating unbiased miRNA profiling [45]. Importantly, the modular and well-defined structure of Gag VLPs was deliberately selected to ensure uniform RNA content across replicates [46], thereby increasing the reproducibility of SNaP for cell-free miRNA profiling. This consistency could offer a substantial advantage over extracellular vehicles (EVs), as they frequently display variability in both composition and RNA content [47]. In line with these features, we used the immunolabeling of the Gag p24 domain as a robust proxy for SNaP production and intracellular distribution. In parallel, independent of p24 staining, we confirmed particle morphology and size by electron microscopy and nanoparticle tracking analysis across multiple packaging cell types, demonstrating comparable size distributions for SNaP particles derived from HEK-293T, BV-2, and HT22 cells.

SNaP stands out from current local transcriptomics methods for its increased specificity in identifying localized miRNA pools with minimal contamination from surrounding environments [14, 32]. The integration of a cell-specific promoter within the Gag cassette effectively confined miRNA packaging to target cell types [27], even amidst the complexity of a heterogeneous culture system. Such minimal genetic manipulation makes SNaP-CSP broadly accessible for CNS applications where miRNAs play a crucial role in cell type or subtype commitment [20]. Adding a further layer of spatial complexity, SNaP serves as an exceptional system for exploring the intricate dynamics of intracellularly localized miRNAs involved in the regulation of neuroplasticity [11]. The incorporation of a G-quadruplex within the DLS module strategically directs Gag localization to post-synaptic regions,




Fig. 3 (See legend on next page.)

significantly enhancing the ability of SNaP to package post-synaptic miRNA species [33]. By massively reducing pre-synaptic miRNA incorporation, the DLS engineering approach surpassed the regional specificity offered by traditional synaptosome fractionation [36]. In line with this, we directly benchmarked SNaP-DLS against synaptosomes, showing similar enrichment of canonical post-synaptic miRNAs but markedly reduced recovery of a pre-synaptic miRNA, consistent with a lower

non-dendritic background in SNaP-derived preparations. Together, these advancements position SNaP-CSP/DLS as a promising tool for elucidating local miRNA (dys-) regulation of CNS development and homeostasis at high spatial resolution. In this context, we view SNaP to be complementary, not a replacement, to established approaches such as synaptosome fractionation, single-cell RNA-seq, laser capture microdissection, Ribosome tagging and Ago2-based miRNA capture, which

(See figure on previous page.)

Fig. 3 Enhancing host miRNA loading with the SNaP-TRBP system. **A**) Schematic representation of the experimental framework for engineered SNaP production in HEK-293T cells. **B**) Quantification of p24 levels in the supernatants of producing cells. The data are presented as the means \pm SEMs from $n=5$ independent VLP production experiments per group. Two-tailed Mann–Whitney U test ($p=0.0556$; $U=3$; not significant). **C**) Representative transmission electron microscopy (TEM) micrographs of chimeric SNaP-TRBP and reference Gag-eGFP particles isolated from HEK-293T supernatants. The right panels show magnified views of the images in the left panel. Scale bar: 100 nm. **D**) Comparative analysis of RNA packaging efficiency, calculated as the ratio of nanoparticle-extracted total RNA to p24 protein content in each sample, between eGFP- (control) and TRBP-functionalized nanoparticles. Box plots display median values, with whiskers indicating the minimum and maximum values across $n=5$ VLP productions per group. Two-tailed Mann–Whitney U test ($p=0.0317$, $U=2$). **E**) Quantification of relative miRNA abundance, defined as the percentage of small RNAs within the 10–40 nucleotide range (highlighted in panel C, *Supplementary Fig. 3*) relative to total small RNA content. The supernatant of mock-transfected cells was used as a control. The data are shown as box plots with median values and whiskers indicating the minimum and maximum values across $n=5$ VLP productions per group. Kruskal–Wallis test ($p<0.0001$; statistic = 12.57), followed by Dunn's post hoc comparisons: control vs. Gag–eGFP, $p=0.0763$; control vs. SNaP–TRBP, $p=0.0004$; Gag–eGFP vs. SNaP–TRBP, $p=0.0763$. **F**) Comparative evaluation of miRNA recovery efficiency in SNaP-TRBP relative to Gag-eGFP VLPs for the top three miRNAs highly expressed in HEK-293T cells. The definition of miRNA recovery efficiency is provided in the *Materials and Methods*. The results are presented as box plots showing the median fold change, with whiskers indicating the minimum and maximum values ($n=5/7$ VLP productions per group). Two-tailed Mann–Whitney test: *hsa-miR-10ap* = 0.0476, $U=6$; *hsa-miR-30ep* = 0.0476, $U=6$; and *hsa-miR-186p* = 0.0476, $U=6$

interrogate distinct molecular species and/or spatial scales [14, 16, 32, 48, 49].

Through the analysis of SNaP-incorporated miRNAs across various mammalian cell models, we confirmed that Gag could effectively incorporate endogenous miRNAs without additional modifications, mirroring the RNA export efficiencies reported for HIV-1 infections [22] and other viral systems [50]. Across all producer cell types, we observed workable transduction/transfection efficiencies (approximately 38–60% in neuronal and microglial cultures), which are sufficient for the proof-of-concept validation presented here but leave room for future optimization. Future gains are anticipated through conditional or cell type-specific promoters, expression tuning, and additional vector engineering, particularly for in vivo applications requiring higher efficiency.

While Gag inherent binding capacity meets the needs of many applications, exploring low-abundance miRNAs in specific subcellular compartments may require advanced export potential [37, 51]. To this end, we significantly increased SNaP miRNA binding in a sequence-independent manner via the TRBP module [38, 39]. SNaP-TRBP miRNA export was twice as effective as unmodified Gag VLPs in HEK-293T cells, with comparable improvements in neuron models. The integrated functionality of the TRBP and DLS domains further supports TRBP engineering as a promising approach for the large-scale recovery of compartmentalized miRNAs, particularly those located at synaptic sites. By increasing the sensitivity of localized transcriptome profiling, the SNaP-TRBP-DLS system offers the potential to advance our understanding of brain region-specific gene expression, extending even to rare cellular and subcellular miRNA populations [17, 18].

In this study, we intentionally focused quantitative analyses on a defined panel of neuronal-enriched, glial-enriched, and control miRNAs, serving as model cargos to rigorously assess cell type- and compartment-specific enrichment. We envision that the significant RNA packaging properties of the SNaP modular system could

support comprehensive genetic payload characterization via Next-Generation Sequencing. Coupling SNaP with miRNA sequencing in defined CNS cell types and subcellular localization variants might allow discovering previously unappreciated localized miRNAs. Through bulk miRNA profiling, we anticipate that SNaP will enable the generation of comprehensive datasets detailing patterned miRNA alterations across a range of physiological and pathological conditions, thereby guiding the discovery of more specific and sensitive biomarkers associated with brain disorders [13].

Overall, this study provides the first in vitro evidence that engineered Gag VLPs can serve as robust platforms for the non-destructive miRNA profiling of distinct brain-like cells, namely iPSC/mESC-derived neurons, HT22 and BV-2 cells, which model the cellularly heterogeneous CNS milieu. These findings align with earlier reports supporting chimeric nanoparticle packaging in clinically relevant lymphoid cell lines [25]. By facilitating spatially resolved miRNA profiling, our findings not only anticipate the scalability of SNaP for in vivo applications but also underscore its potential for the longitudinal evaluation of miRNA dynamics over time. Nevertheless, while our exploratory assessments offer valuable insights for these applications, we recognize that a more in-depth characterization will be beneficial to fully substantiate future in vivo implementations. From a technical perspective, this study is intentionally scoped as an in vitro proof-of-concept; consequently, aspects of SNaP performance will require evaluation in intact tissues in future studies. With this regard, at the developmental stages analyzed for human iPSC-derived neurons, mature axonal polarization is incomplete and processes are more appropriately referred to as neurites [58]. Accordingly, we interpret SNaP miRNA recovery as reflecting neuritic (pre-synaptic) versus post-synaptic localization, rather than a definitive segregation between axonal and dendritic compartments.

In addition, for dendritic localization analyses of SNaP-DLS, we prioritised super-resolution imaging of the p24




Fig. 4 (See legend on next page.)

(See figure on previous page.)

Fig. 4 Dual functionalization of SNaP with DLS and TRBP modules enhances the recovery of post-synaptic miRNAs from nanoparticles. **A**) Schematic representation of single (SNaP-DLS) and dual-engineered (SNaP-TRBP-DLS) VLP production in mouse embryonic stem cell (mESC)-derived neurons. **B**) Representative confocal microscopy images showing the localization of chimeric SNaP, SNaP-DLS, and SNaP-TRBP-DLS within mature DIV28 packaging neurons, visualized via p24 staining (green). Post-synaptic compartments are marked by Homer 1b/c (red), and nuclei are counterstained with DAPI (blue). Mock-transduced cells were used as controls. Scale bar: 50 μ M. **C**) Quantification of p24 and Homer 1b/c colocalization, expressed as the percentage of ROI overlap. Statistical comparisons among the SNaP (light gray), SNaP-DLS (dark gray), and SNaP-TRBP-DLS (red) groups were performed via a Kruskal–Wallis test ($p=0.0013$, statistic = 13.23), followed by Dunn's post hoc analysis: SNaP vs. SNaP-DLS ($p=0.0036$), SNaP vs. SNaP-TRBP-DLS ($p=0.0010$), and SNaP-DLS vs. SNaP-TRBP-DLS ($p=0.4077$, not significant). Data are presented as box plots showing the median with range (whiskers, $n=10$ –18 images per group from $n=2$ independent experiments). **D**) Comparative analysis of nanoparticle miRNA recovery efficiency in DIV25–DIV28 collected SNaP-TRBP-DLS relative to SNaP-DLS for the triplet of post-synaptically localized miRNAs, expressed as detailed in the *Materials and Methods*. The data were adjusted for background miRNA levels in mock-transduced cell media and are presented as the median fold change with range (whiskers, $n=6$ –7 SNaP productions per group). Two-tailed Mann–Whitney U test: *mmu-miR-132* ($p=0.0476$, $U=6$), *mmu-miR-134* ($p=0.0476$, $U=6$), and *mmu-miR-138* ($p=0.0012$, $U=0$)

domain in relation to post-synaptic markers, rather than employing miRNA FISH or chromogenic in situ hybridization to directly visualize captured transcripts. Our choice reflects methodological constraints, as available chromogenic ISH/IHC protocols lack the spatial resolution required to confidently resolve signals within fine neuritic compartments, while alternative approaches (such as conventional miRNA ISH or expansion-based methods) can dilute or blur compartmentalized miRNA signals, complicating precise subcellular assignment [53, 54].

Furthermore, we acknowledge that our quantitative analyses intentionally target a defined panel of miRNAs used as model cargos to rigorously test cell-type and compartment-specific enrichment. Transcriptome-wide assessments of packaging fidelity and discovery of novel localized miRNAs will require coupling SNaP to miRNA sequencing.

While SNaP-CSP (i.e. Cell-Specific Promoter) has been validated in neurons and microglia, extension of the platform to additional CNS cell types, most notably astrocytes and their distinct reactive states, as well as diverse neuronal subtypes [55, 56], represents an important opportunity to broaden its discovery potential. Finally, the challenges of blood–brain barrier penetration, cell type-specific targeting in intact CNS tissues and long-term safety have not yet been experimentally addressed and will require dedicated ex vivo and in vivo studies, for which the present in vitro framework provides a necessary technological foundation.

In light of these points, the path toward ex vivo and in vivo applications will require several additional engineering and validation steps. For systemic administration, SNaP will likely need surface modifications that promote blood-brain barrier crossing [34, 57], whereas local CNS delivery could exploit intracerebral or intrathecal routes. Cell type specificity in intact tissues will probably rely on the combination of cell type-restricted or inducible promoters and tailored surface engineering (e.g. pseudotyping or ligand display) to restrict SNaP expression and/or uptake to defined neuronal and glial populations. Early feasibility can be evaluated via stereotaxic injections in

rodents, acute brain slices, or brain organoids. Rigorous assessment of immunogenicity, durability of SNaP expression, and potential physiological effects will be essential. Together, these steps outline a practical roadmap from the current in vitro proof-of-concept to future ex vivo and in vivo implementations.

Conclusions

In summary, this study introduces synthetic nanoparticles for precise miRNA loading and export (SNaP) as a robust, versatile, highly tunable platform for high-resolution profiling of endogenous microRNAs within cellularly heterogeneous systems. In the current work, these properties are demonstrated in vitro in neuronal and microglial models that mimic aspects of CNS cellular heterogeneity. This approach is fundamentally original, as unlike the conventional use of VLPs for targeted *delivery* of therapeutic molecules into target cells, SNaP leverages its novel redesign for the *export* and *recovery* of molecular cargo. This work establishes three critical advancements. First, the modular design enables cell type-specific miRNA export within an heterogeneous cellular brain-like system. Second, the integration of a dendritic localization signal dramatically enhances spatial resolution, allowing for unprecedented, low-background capture of post-synaptic, compartmentalized miRNAs. Finally, functionalization with the TRBP module significantly increases both the sensitivity and unbiased nature of miRNA capture, an effect that is synergistic when combined with DLS for maximizing post-synaptic miRNA recovery. These combined results validate SNaP-TRBP-DLS as a powerful, multidomain engineered tool. The platform's ability to precisely map miRNAs across cell types and subcellular compartments represents a crucial technical leap forward. This level of spatial and molecular precision is essential for dissecting the intricate regulatory roles of miRNAs in neuronal function, plasticity, and pathology, thereby offering a transformative approach for investigating neurological diseases and advancing our understanding of the molecular landscape of the brain. Looking ahead, the same modular design can be extended to additional CNS cell types,

including astrocytes, and coupled to miRNA sequencing and advanced delivery strategies in ex vivo and in vivo settings, providing a foundation for discovery-oriented and translational studies of localized miRNA regulation in the brain.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12951-026-04034-9>.

Supplementary Material 1

Acknowledgements

The authors wish to acknowledge M. Calvello, S. Lisi, V. Liverani, A. Viegi, and M. Sanguanini (Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Pisa) for their valuable technical assistance, E. Chiavacci, A. Allouch and L. Pandolfini for valuable discussions and L. Poliseo (Institute of Clinical Physiology, National Research Council of Pisa) for access to equipment. We are also grateful to Dr. M. Ward (NINDS, NIH) for providing human i3-induced pluripotent stem cells (iPSCs) and the NIH AIDS reagent program for providing the mouse anti-HIV-1 p24 monoclonal antibody and the pGag-eGFP construct.

Author contributions

AC and CDP conceived the initial idea, and C.D.P. conceived the project. C.D.P., M.M., G.S., M.R., and M.C.C. contributed to the experimental design. M.M., V.I., A.S., E.O., L.M., V.C., E.N., L.F., A.A. and G.G. conducted the experiments. C.D.P. supervised the study. M.C.C. and R.W.M. supervised the human neuron work. A.C., F.C. and R.W.M. obtained research funding and contributed to critical supervision and project leadership. M.M. wrote the manuscript, and AC and CDP revised the manuscript. All the authors read and approved the final manuscript.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by EU funding within the Next-Generation EU-MUR PNRR TUSCANY HEALTH Ecosystem (THE) (project no. ECS_00000017), which spoke 8 to AC. and CDP; Scuola Normale institutional funds to AC; PRIN2022 to AC.; PRIN2022 to C.D.P.; M.C.C. and R.W.M. are supported by the Wellcome Trust (grant ref. 223202/Z/21/Z).

Data availability

The microarray dataset of synaptosomal miRNAs analysed in this work is openly available at [<https://www.synapse.org/#!Synapse:syn26642975/files/>] (<https://www.synapse.org>), Synapse ID: [syn26642975] (<https://www.synapse.org>). All other data generated throughout this study are included in the manuscript and/or Supplementary Information.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Marianna Mignanelli is currently an employee and stock owner at AstraZeneca UK Ltd., UK. Giacomo Siano is currently employed at F. Hoffmann-La Roche AG, Switzerland. The remaining authors have no conflicts of interest to declare.

Author details

¹Laboratorio di Biologia Bio@SNS, Scuola Normale Superiore, Via G. Moruzzi 1, Pisa 56126, Italy

²Institute of Neuroscience, Italian National Research Council (CNR), Via G. Moruzzi 1, Pisa 56126, Italy

³Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa 56127, Italy

⁴Institute of Clinical Physiology, Italian National Research Council (CNR), Via G. Moruzzi 1, Pisa 56126, Italy

⁵Oxford Parkinson's Disease Centre, Department of Physiology, Anatomy and Genetics, University of Oxford, Sherrington Building, Sherrington Road, Oxford OX1 3PT, UK

⁶Kavli Institute for Neuroscience Discovery, University of Oxford, Dorothy Crowfoot Hodgkin Building, South Park Road, Oxford OX1 3QU, UK

⁷Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, Pisa 56126, Italy

⁸Laboratory of Basic and Applied Medical Sciences, Unit of Translational Critical Care Medicine, Interdisciplinary Research Center Health Science, Scuola Superiore Sant'Anna, Pisa 56127, Italy

Received: 28 October 2025 / Accepted: 7 January 2026

Published online: 27 January 2026

References

- He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet.* 2004;5:522–31.
- Jovičić A, et al. Comprehensive expression analyses of neural cell-type-specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. *Ann Intern Med.* 2013;158:5127–37.
- Kawase-Koga Y, et al. Rnaase-III enzyme dicer maintains signaling pathways for differentiation and survival in mouse cortical neural stem cells. *J Cell Sci.* 2010;123:586–94.
- Sempere LF, et al. Expression profiling of mammalian MicroRNAs uncovers a subset of brain-expressed MicroRNAs with possible roles in murine and human neuronal differentiation. *Genome Biol.* 2004;5(3):R13.
- Schratt GM, et al. A brain-specific MicroRNA regulates dendritic spine development. *Nature.* 2006;439:283–9.
- Hu Z, Li Z. Mirnas in synapse development and synaptic plasticity. *Curr Opin Neurobiol.* 2017;45:24–31.
- Fénelon K, et al. Deficiency of Dgcr8, a gene disrupted by the 22q11.2 microdeletion, results in altered short-term plasticity in the prefrontal cortex. *Proc Natl Acad Sci U S A.* 2011;108:4447–52.
- Aksoy-Aksel A, Zampa F, Schratt G. MicroRNAs and synaptic plasticity—a mutual relationship. *Philos Trans R Soc Lond B Biol Sci.* 2014. <https://doi.org/10.1098/rstb.2013.0515>.
- Ashraf SI, McLoon AL, Sclarsic SM, Kunes S. Synaptic protein synthesis associated with memory is regulated by the RISC pathway in drosophila. *Cell.* 2006;124:191–205.
- Banerjee S, Neveu P, Kosik KS. A coordinated local translational control point at the synapse involving relief from silencing and MOV10 degradation. *Neuron.* 2009;64:871–84.
- Brennan GP, Henshall DC. MicroRNAs as regulators of brain function and targets for treatment of epilepsy. *Nat Rev Neurol.* 2020;16:506–19.
- Hoss AG, Labadorf A, Beach TG, Latourelle JC, Myers RH. MicroRNA profiles in parkinson's disease prefrontal cortex. *Front Aging Neurosci.* 2016;8:36. <https://doi.org/10.3389/fnagi.2016.00036>
- Condrat CE, et al. MiRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. *Cells.* 2020. <https://doi.org/10.3390/cells9020276>.
- Perez JD, Schuman EM. Subcellular RNA-seq for the analysis of the dendritic and somatic transcriptomes of single neurons. *Bio Protoc.* 2022;12(1):e4278. <https://doi.org/10.21769/BioProtoc.4278>
- Trebesova H, Grilli M. Synaptosomes: a functional tool for studying neuroinflammation. *Encyclopedia.* 2023;3:406–18.
- Cajigas IJ, et al. The local transcriptome in the synaptic neuropil revealed by deep sequencing and high-resolution imaging. *Neuron.* 2012;74(3):453–66.
- Hücker SM, et al. Single-cell microRNA sequencing method comparison and application to cell lines and circulating lung tumor cells. *Nat Commun.* 2021. <https://doi.org/10.1038/s41467-021-24611-w>.
- Piwecka M, Rajewsky N, Rybak-Wolf A. Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease. *Nat Rev Neurol.* 2023;19:346–62.
- Maji RK, Leisegang MS, Boon RA, Schulz MH. Revealing microrna regulation in single cells. *Trends Genet.* 2025;41:522–36.

20. Zolboot N, Du JX, Zampa F, Lippi G. MicroRNAs instruct and maintain cell type diversity in the nervous system. *Front Mol Neurosci*. 2021. <https://doi.org/10.3389/fnmol.2021.646072>.
21. Martins SA, et al. How promising are HIV-1-based virus-like particles for medical applications. *Front Cell Infect Microbiol*. 2022. <https://doi.org/10.3389/fcimb.2022.997875>.
22. Bogerd HP, Kennedy EM, Whisnant AW, Cullen BR. Induced packaging of cellular micRNAs into HIV-1 virions can inhibit infectivity. *mBio*. 2017. <https://doi.org/10.1128/mBio.02125-16>.
23. Cimarelli A, Sandin S, Höglund S, Höglund H, Luban J. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. *J Virol*. 2000;74. <https://doi.org/10.1128/jvi.74.7.3046-3057.2000>
24. Cervera L, et al. Production of HIV-1-based virus-like particles for vaccination: achievements and limits. *Appl Microbiol Biotechnol*. 2019;103:7367–84.
25. Horns F, et al. Engineering RNA export for measurement and manipulation of living cells. *Cell*. 2023;186:3642-3658.e32.
26. McKenzie AT, et al. Brain cell type specific gene expression and co-expression network architectures. *Sci Rep*. 2018. <https://doi.org/10.1038/s41598-018-27293-5>.
27. Boulaire J, Balani P, Wang S. Transcriptional targeting to brain cells: engineering cell type-specific promoter containing cassettes for enhanced transgene expression. *Adv Drug Deliv Rev*. 2009;61:589–602.
28. Phillips RJ, Hargrave SL, Rhodes BS, Zopf DA, Powley TL. Quantification of neurons in the myenteric plexus: an evaluation of putative pan-neuronal markers. *J Neurosci Methods*. 2004;133:99–107.
29. Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. *Glia*. 1993;7(1):9–18.
30. Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macrophage-specific protein Iba1 binds to fibronectin and enhances its actin-bundling activity. *J Neurochem*. 2004;88:844–56.
31. Yasuda R, Hayashi Y, Hell JW. CaMKII: a central molecular organizer of synaptic plasticity, learning and memory. *Nat Rev Neurosci*. 2022;23:666–82.
32. Hafner AS, Donlin-Asp PG, Leitch B, Herzog E, Schuman EM. Local protein synthesis is a ubiquitous feature of neuronal pre- and post-synaptic compartments. *Science*. 1979;364:2019.
33. Subramanian M, et al. G-quadruplex RNA structure as a signal for neurite mRNA targeting. *EMBO Rep*. 2011;12:697–704.
34. Puhl DL, D'Amato AR, Gilbert RJ. Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. *Brain Res Bull*. 2019;150:216–30.
35. Bicker S, Lackinger M, Weiß K, Schrat G. MicroRNA-132, -134, and -138: a microRNA trioka rules in neuronal dendrites. *Cell Mol Life Sci*. 2014;71:3987–4005.
36. Kumar S, et al. Synaptosome microRNAs regulate synapse functions in Alzheimer's disease. *NPJ Genom Med*. 2022. <https://doi.org/10.1038/s41525-022-00319-8>.
37. Koshiol J, Wang E, Zhao Y, Marincola F, Landi MT. Strengths and limitations of laboratory procedures for microRNA detection. *Cancer Epidemiol Biomarkers Prev*. 2010;19:907–11.
38. Benoit MPMH, et al. The RNA-binding region of human TRBP interacts with microRNA precursors through two independent domains. *Nucleic Acids Res*. 2013;41:4241–52.
39. Fareh M, et al. TRBP ensures efficient Dicer processing of precursor microRNA in RNA-crowded environments. *Nat Commun*. 2016;7:1–11.
40. Gutiérrez-Granados S, Cervera L, Godia F, Segura MM. Characterization and quantitation of fluorescent Gag virus-like particles. *BMC Proc*. 2013. <https://doi.org/10.1186/1753-6561-7-56-P62>.
41. Cervera L, et al. Generation of HIV-1 gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. *J Biotechnol*. 2013;166:152–65.
42. Panwar B, Omenn GS, Guan Y. MiRmine: a database of human miRNA expression profiles. *Bioinformatics*. 2017;33:1554–60.
43. Ganser-Pornillos BK, Yeager M, Sundquist WJ. The structural biology of HIV assembly. *Curr Opin Struct Biol*. 2008;18:203–17.
44. Liu Y, et al. HIV-1 Sequence Necessary and Sufficient to Package Non-viral RNAs into HIV-1 Particles. *J Mol Biol*. 2017;429:2542–55.
45. Chen AK, et al. MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production. *Proc Natl Acad Sci USA*. 2014. <https://doi.org/10.1073/pnas.1408037111>.
46. de Marco A, et al. Conserved and Variable Features of Gag Structure and Arrangement in Immature Retrovirus Particles. *J Virol*. 2010;84:11729–36.
47. Veziroglu EM, Mias GI. Characterizing extracellular vesicles and their diverse RNA contents. *Front Genet*. 2020. <https://doi.org/10.3389/fgene.2020.00700>.
48. Holt CE, Schuman EM. The central dogma decentralized: new perspectives on RNA function and local translation in neurons. *Neuron*. 2013;80:648–57.
49. Alon S, et al. Expansion sequencing: spatially precise in situ transcriptomics in intact biological systems. *Science*. 1979;371:2021.
50. Prel A, et al. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles. *Mol Ther Methods Clin Dev*. 2015;2:15039.
51. Benesova S, Kubista M, Valihrach L. Small rna-sequencing: approaches and considerations for mirna analysis. *Diagnostics*. 2021. <https://doi.org/10.3390/diagnostics11060964>.
52. Segel M, et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. *Science (New York, NY)*. 2021;373(6557):882–9.
53. Robles-Remacho A, Zou Y, Grillo M, Nilsson M. Spatially resolved microRNA expression in tissues: technologies, challenges, and opportunities. *Trends Genet*. 2025. <https://doi.org/10.1016/j.tig.2025.06.005>.
54. Pringle NP, Richardson WD. In Situ Hybridization Protocols. <https://www.ucl.ac.uk/~ucbzwdr/In%20Situ%20Protocol.pdf>
55. He M, et al. Cell-type-based analysis of microRNA profiles in the mouse brain. *Neuron*. 2012;73:35–48.
56. Delzor A, et al. Restricted transgene expression in the brain with cell-type specific neuronal promoters. *Hum Gene Ther Methods*. 2012;23:242–54.
57. Wu D, et al. The blood–brain barrier: structure, regulation, and drug delivery. *Signal Transduct Target Ther*. 2023. <https://doi.org/10.1038/s41392-023-01481-w>.
58. Wang C, et al. Scalable production of iPSC-derived human neurons to identify tau-lowering compounds by high-content screening. *Stem Cell Rep*. 2017;9:1221–33.
59. Fernandopulle MS, et al. Transcription factor-mediated differentiation of human iPSCs into neurons. *Curr Protoc Cell Biol*. 2018. <https://doi.org/10.1002/cpcb.51>.
60. Bertacchi M, et al. The positional identity of mouse ES cell-generated neurons is affected by BMP signaling. *Cell Mol Life Sci*. 2013;70:1095–111.
61. Lupo G, et al. From pluripotency to forebrain patterning: an in vitro journey astride embryonic stem cells. *Cell Mol Life Sci*. 2014;71:2917–30.
62. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res*. 2001. <https://doi.org/10.1093/nar/29.9.e45>.
63. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta CT$ method. *Methods*. 2001;25:402–8.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.